Filippi M, Rovaris M, Capra R, Gasperini C, Yousry T A, Sormani M P, Prandini F, Horsfield M A, Martinelli V, Bastianello S, Kühne I, Pozzilli C, Comi G
Department of Neuroscience, Scientific Institute, Ospedale San Raffaele, University of Milan, Italy.
Brain. 1998 Oct;121 ( Pt 10):2011-20. doi: 10.1093/brain/121.10.2011.
In this study we assessed the safety, efficacy and cost-effectiveness of the use of triple dose gadolinium-DTPA (Gd) in serial monthly brain MRI of patients with multiple sclerosis, such as could be selected for clinical trials. The number of enhancing lesions, the number of new enhancing lesions and the number of active scans were used to evaluate the sensitivity of the contrast-enhanced MRI to disease activity. The dose of Gd, and the effect of introducing a delay between the contrast injection and the scan were both appraised. Every 4 weeks for 3 months, and in two separate sessions, scans were obtained from 40 patients with relapsing-remitting or secondary progressive multiple sclerosis, 5 min (early) and 20 min (delayed) after a standard dose (0.1 mmol/kg) or triple dose (0.3 mmol/kg) Gd injection. There were 435 enhancing lesions (242 of which were new) on the early standard dose scans, 479 (263 new) on the delayed standard dose, 772 (365 new) on the early triple dose and 827 (404 new) on the delayed triple dose. There were 109 scans revealing active disease on the early standard dose scans, 112 on the delayed standard dose, 119 on the early triple dose and 120 on the delayed triple dose. Statistical simulations indicated that the sample sizes needed for both cross-over and parallel-group trials with similar powers are lower if serial monthly triple dose MRI is used. No side-effects were reported and no significant changes in blood test parameters were found throughout the study. This study shows that the serial use of triple dose Gd is safe, and that it increases the sensitivity of serial monthly enhanced MRI in detecting multiple sclerosis activity significantly. Its use should enable preliminary trials of experimental therapies for multiple sclerosis to be conducted in small patient populations, over a short period of time.
在本研究中,我们评估了在可入选临床试验的多发性硬化症患者每月进行的脑部磁共振成像(MRI)检查中使用三倍剂量钆喷酸葡胺(Gd)的安全性、有效性和成本效益。通过强化病灶数量、新增强化病灶数量和活跃扫描次数来评估对比增强MRI对疾病活动的敏感性。同时评估了Gd的剂量以及在注射造影剂与扫描之间引入延迟的效果。在3个月内,每4周进行一次扫描,分两个独立阶段,对40例复发缓解型或继发进展型多发性硬化症患者在注射标准剂量(0.1 mmol/kg)或三倍剂量(0.3 mmol/kg)Gd后的5分钟(早期)和20分钟(延迟)进行扫描。早期标准剂量扫描中有435个强化病灶(其中242个为新增病灶),延迟标准剂量扫描中有479个(263个新增),早期三倍剂量扫描中有772个(365个新增),延迟三倍剂量扫描中有827个(404个新增)。早期标准剂量扫描中有109次扫描显示存在活动性疾病,延迟标准剂量扫描中有112次,早期三倍剂量扫描中有119次,延迟三倍剂量扫描中有120次。统计模拟表明,如果使用每月一次的三倍剂量MRI,具有相似效能的交叉试验和平行组试验所需的样本量会更低。在整个研究过程中未报告有副作用,血液检测参数也未发现显著变化。本研究表明,连续使用三倍剂量Gd是安全的,并且它能显著提高每月一次的增强MRI检测多发性硬化症活动的敏感性。其应用应能使针对多发性硬化症的实验性疗法在小患者群体中、在短时间内进行初步试验。